文献速递流行病学与生物统计临床试验与 GCP

药物洗脱支架植入后合并或不合并糖尿病患者短期与长期双联抗血小板治疗的比较:随机试验个体参与者数据的系统综述与Meta分析

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.
PubMed 文献 · BMJ · 2016-11-03

本研究纳入6项随机试验共11473例患者,比较药物洗脱支架植入后短期(≤6个月)与长期(12个月)双联抗血小板治疗(DAPT)的临床结局。糖尿病是主要不良心血管事件(MACE)的独立预测因素(HR 2.30)。长期DAPT未降低MACE风险,但增加出血风险,无论是否合并糖尿病。

要点

  • 糖尿病是药物洗脱支架植入后MACE的独立预测因素,HR 2.30(95%CI 1.01-5.27;P=0.048)。
  • 长期DAPT与短期DAPT相比,合并或不合并糖尿病患者MACE风险均无显著差异。
  • 长期DAPT增加大出血或小出血风险,与是否合并糖尿病无关。

核心结论

  • 糖尿病是药物洗脱支架植入后MACE的独立预测因素,但长期DAPT与短期DAPT相比未降低MACE风险,反而增加出血风险,无论是否合并糖尿病。

研究设计与样本

  • 个体参与者数据Meta分析,纳入6项比较药物洗脱支架植入后DAPT时长的随机对照试验,共11473例随机患者。
  • 采用按试验分层的Cox比例回归模型评估糖尿病对结局的影响,所有分析按意向治疗进行。

主要发现

  • 6项试验共纳入11473例患者,其中3681例(32.1%)合并糖尿病,7708例(67.2%)不合并糖尿病,84例(0.7%)信息缺失;平均年龄分别为63.7岁(SD 9.9)和62.8岁(SD 10.1)。
  • 糖尿病是MACE的独立预测因素(HR 2.30,95%CI 1.01-5.27;P=0.048)。
  • 随访1年时,长期DAPT与短期DAPT相比,合并糖尿病患者MACE风险无显著差异(HR 1.05,95%CI 0.62-1.76;P=0.86),不合并糖尿病患者亦无显著差异(HR 0.97,95%CI 0.67-1.39;P=0.85),交互作用P=0.33。
  • 心肌梗死风险在两种DAPT方案间无显著差异:合并糖尿病者HR 0.95(95%CI 0.58-1.54;P=0.82),不合并糖尿病者HR 1.15(95%CI 0.68-1.94;P=0.60),交互作用P=0.84。
  • 长期DAPT在合并糖尿病患者中降低明确/ probable支架血栓风险(HR 0.26,95%CI 0.09-0.80;P=0.02),不合并糖尿病患者无显著差异(HR 1.42,95%CI 0.68-2.98;P=0.35),交互作用P=0.04;但landmark分析显示两组均有获益趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare clinical outcomes between short term (up to 6 months) and long term (12 months) dual antiplatelet therapy (DAPT) after placement of a drug eluting stent in patients with and without diabetes. DESIGN: Individual participant data meta-analysis. Cox proportional regression models stratified by trial were used to assess the impact of diabetes on outcomes. DATA SOURCE: Medline, Embase, and Cochrane databases and proceedings of international meetings searched for randomised controlled trials comparing durations of DAPT after placement of a drug eluting stent. Individual patient data pooled from six DAPT trials. PRIMARY OUTCOME: Primary study outcome was one year risk of major adverse cardiac events (MACE), defined as cardiac death, myocardial infarction, or definite/probable stent thrombosis. All analyses were conducted by intention to treat. RESULTS: Six trials including 11 473 randomised patients were pooled. Of these patients, 3681 (32.1%) had diabetes and 7708 (67.2%) did not (mean age 63.7 (SD 9.9) and 62.8 (SD 10.1), respectively), and in 84 (0.7%) the information was missing. Diabetes was an independent predictor of MACE (hazard ratio 2.30, 95% confidence interval 1.01 to 5.27; P=0.048 At one year follow-up, long term DAPT was not associated with a decreased risk of MACE compared with short term DAPT in patients with (1.05, 0.62 to 1.76; P=0.86) or without (0.97, 0.67 to 1.39; P=0.85) diabetes (P=0.33 for interaction). The risk of myocardial infarction did not differ between the two DAPT regimens (0.95, 0.58 to 1.54; P=0.82; for those with diabetes and 1.15, 0.68 to 1.94; P=0.60; for those without diabetes (P=0.84 for interaction). There was a lower risk of definite/probable stent thrombosis with long term DAPT among patients with (0.26, 0.09 to 0.80; P=0.02) than without (1.42, 0.68 to 2.98; P=0.35) diabetes, with positive interaction testing (P=0.04 for interaction), although the landmark analysis showed a trend towards benefit in both groups. Long term DAPT was associated with higher rates of major or minor bleeding, irrespective of diabetes (P=0.37 for interaction). CONCLUSIONS: Although the presence of diabetes emerged as an independent predictor of MACE after implantation of a drug eluting stent, compared with short term DAPT, long term DAPT did not reduce the risk of MACE but increased the risk of bleeding among patients with stents with and without diabetes.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Gargiulo G, Windecker S, da Costa BR, et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ. 2016. PMID: 27811064. doi:10.1136/bmj.i5483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。